Krystal Biotech (NASDAQ:KRYS) Releases Earnings Results, Beats Estimates By $0.26 EPS

Krystal Biotech (NASDAQ:KRYS) announced its quarterly earnings results on Monday. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.26, FiscalAI reports. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million.

Krystal Biotech Price Performance

KRYS opened at $332.29 on Monday. The company has a market capitalization of $9.84 billion, a P/E ratio of 41.64 and a beta of 0.50. Krystal Biotech has a 52 week low of $184.02 and a 52 week high of $382.54. The stock’s fifty day moving average is $337.46 and its two-hundred day moving average is $308.68.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Jefferies Financial Group restated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a report on Monday, July 13th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Wednesday, September 23rd. HC Wainwright restated a “buy” rating and issued a $361.00 target price on shares of Krystal Biotech in a report on Thursday, October 15th. Royal Bank Of Canada began coverage on shares of Krystal Biotech in a research note on Friday, August 14th. They set an “outperform” rating and a $400.00 price target for the company. Finally, Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $377.20.

Insider Transactions at Krystal Biotech

In other news, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.